Loading data for TSHA — first visit, this takes a few seconds.

알림

Taysha Gene Therapies Inc... (TSHA)

NasdaqGS: TSHA · 실시간 가격 · USD

6.43

+0.24 (3.88%)

종가 기준: Aug 19, 2026, 2:29 PM

3.88% (1D)

데이터 없음

매수호가	n/a
시가총액	2.1B
매출 (ttm)	5.49M
순이익 (ttm)	-149.63M
베타	1.19
EPS (ttm)	-0.41
P/E (ttm)	n/a
선행 P/E	-13.47
P/B (ttm)	8.71
P/S (ttm)	381.97
Earnings Date	Nov 4, 2026

매도호가	n/a
거래량	218,514
평균 거래량 (20일)	3,096,825
시가	6.40
전일 종가	6.19
일중 범위	6.29 - 6.46
52주 범위	2.71 - 7.30
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

TSHA 소개

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 24, 2020

직원 수 99

상장 거래소 NasdaqGS

티커 TSHA

웹사이트 https://www.tayshagtx.com

전체 기업 정보

재무 실적

2025년 Taysha Gene Therapies의 매출은 9.77M로, 전년 8.33M 대비 17.28% 증가했습니다. 순이익은 -109M로, 22.06% 증가했습니다.

재무제표

어닝 서프라이즈

Taysha Gene Therapies가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.

EPS -0.13 예상치 하회 -0.02, 및 -62.50% 전년 대비 감소.

다음 실적 발표

Taysha Gene Therapies Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · Simply Wall St.

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and ...

1주 전 · Moby

Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary

Moby summary of Taysha Gene Therapies, Inc.'s Q2 2026 earnings call

1주 전 · GuruFocus.com

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

Company reports 100% response rate in Part A trial, completes pivotal dosing, and maintains $455.4 million cash position into 2028

1주 전 · MarketBeat

Taysha Gene Therapies Q2 Earnings Call Highlights

Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential bi...

1개월 전 · Insider Monkey

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now. On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten publ...

2 페이지 중 1

Taysha Gene Therapies Inc... (TSHA)